The study was done to investigate the diagnostic value and regulatory mechanism of miR-200a targeting ZEB1 in PIH.

The expression of miR-200a and ZEB1 was detected in the placenta of PIH patients, and then the human trophoblastic cell line JEG-3 was transfected and divided into different groups: control group, NC group, ZEB1 siRNA group, miR-200a inhibitor group, and miR-200a inhibitor group + ZEB1 siRNA group.

The expression of miR-200a was gradually increased in the placenta of patients with hypertension and mild or severe preeclampsia, while the mRNA and protein levels of ZEB1 were downregulated. A dual-luciferase reporter assay was performed to confirm the targeting relationship between miR-200a andZEB1. These parameters were then compared to the control, However, no significant alteration was observed in the miR-200a level after administration of ZEB1 siRNA, while ZEB1 was downregulated, with significant suppression of growth.

The findings of the study concluded that MiR-200a was upregulated in PIH patients, and inhibition of miR-200a may improve disease progression, as it could facilitate trophoblast proliferation, migration, and invasion, and inhibit apoptosis by targeting ZEB1.

Reference: https://www.tandfonline.com/doi/full/10.1080/10641955.2020.1757700